NCT/Study#

NCT04919811 /

AB-106-G208

Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study

Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study

DISEASE GROUP:
Lung
current phase:
II
STUDY STATUS:
Active
Location:
For More information: